| Literature DB >> 35732910 |
Lorena De La Mora1, Ainoa Ugarte1, Josep Mallolas1, Montserrat Laguno1, Maria Martínez-Rebollar2, Elisa De Lazzari1, David García-Hernández1, Guillermo Font1, Nicolás De Loredo1, Estela Solbes1, Laia Miquel3, Jordi Blanch3, Berta Torres1, Josep Riera4, Iván Chivite1, Juan Ambrosioni1, Alexy Inciarte1, Ana González-Cordón1, Esteban Martínez1, José Luis Blanco1.
Abstract
Pre-exposure prophylaxis (PrEP) is a biomedical intervention that has demonstrated efficacy in HIV prevention in individuals at high-risk, among them chemsex users. Out of 190 PrEP users followed at Hospital Clinic of Barcelona until October 2020, 89% reported drug use, and 63% disclosed that they had engaged in chemsex practices, initiated in 64% of cases within the past year. Twenty-one percent used 3 or more drugs simultaneously, being GHB/GBL, nitrites, sildenafil, and methamphetamine the most prevalent combination. Eight percent reported slamming. Forty-one percent described having had negative experiences and 8% did not remember the last time they had sober sex. Methamphetamine, mephedrone, GHB/GBL, and having had open relationships, group sex, double penetration, and fisting were significantly more prevalent. Forty-nine percent admitted being worried about chemsex use, and 18% said they needed help. A comprehensive, interdisciplinary approach is mandatory to enable the attainment of a healthy approach to one's sex life.Entities:
Keywords: Chemsex; GBMSM; PrEP; Sex life
Year: 2022 PMID: 35732910 DOI: 10.1007/s10461-022-03730-5
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165